Patents by Inventor Juan Pablo Senosiain Peláez
Juan Pablo Senosiain Peláez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220370391Abstract: The present disclosure relates to: a solid compound formed by curcumin and arginine, which includes molar ratios between 5:1 and 1:5, with improved bioavailability properties, and which contains a solid compound comprising curcumin and arginine; the use thereof in complaints of inflammation, pain, stiffness and reduced range of movement, and in complaints that cause disability owing to the presentation of symptoms of pain, inflammation and stiffness and reduced range of movement, among others; and a pharmaceutical composition containing curcumin and L-arginine with a synergic effect in the therapeutic activity of the combination of curcumin and L-arginine, wherein the selected ratio allows a synergic effect in the therapeutic activity thereof to be obtained, and wherein an exemplary preferred ratio of curcumin to L-arginine is between 5:1 to 1:5.Type: ApplicationFiled: July 31, 2020Publication date: November 24, 2022Applicant: ALPARIS, S.A. DE C.V.Inventors: Jorge Guillermo DOMÍNGUEZ CHÁVEZ, Karina MONDRAGÓN VÁSQUEZ, Juan Pablo SENOSIAIN PELÁEZ
-
Patent number: 10301316Abstract: New amorphous solid phases of sitagliptin with derivatives of hydroxybenzoic acids, dihydroxybenzoic acids and trihydroxybenzoic acids as coformers; the obtained new solid phases possess enhanced pharmaceutical properties such as enhanced solubility and higher dissolution rate, as compared to the sitagliptin phosphate monohydrate, and they are also stable under ambient conditions.Type: GrantFiled: December 8, 2017Date of Patent: May 28, 2019Assignee: ALPARIS, S.A. DE C.V.Inventors: Jorge Guillermo Domínguez Chávez, Karina Mondragón Vásquez, Juan Pablo Senosiain Peláez
-
Patent number: 10207982Abstract: The present invention refers to new amorphous and crystalline solid forms of desvenlafaxine, also known as O-desmethylvenlafaxine or desmethylvenlafaxine, and to its salts, solvates, hydrates and polymorphs thereof, as well as to their use in the manufacture of a pharmaceutical composition useful in the treatment of depression and/or as a selective serotonin and norepinephrine reuptake inhibitor and also in menopause-associated vasomotor disorders.Type: GrantFiled: June 29, 2017Date of Patent: February 19, 2019Assignee: Alparis, S.A. DE C.V.Inventors: Jorge Guillermo Domínguez Chávez, Karina Mondragón Vásquez, Hugo Morales Rojas, Dea Herrera Ruiz, Herbert Höpfl, Reyna Reyes Martínez, Javier Hernández Illescas, Juan Pablo Senosiain Peláez
-
Publication number: 20180170937Abstract: New amorphous solid phases of sitagliptin with derivatives of hydroxybenzoic acids, dihydroxybenzoic acids and trihydroxybenzoic acids as coformers; the obtained new solid phases possess enhanced pharmaceutical properties such as enhanced solubility and higher dissolution rate, as compared to the sitagliptin phosphate monohydrate, and they are also stable under ambient conditions.Type: ApplicationFiled: December 8, 2017Publication date: June 21, 2018Inventors: Jorge Guillermo DOMÍNGUEZ CHÁVEZ, Karina Mondragón VÁSQUEZ, Juan Pablo SENOSIAIN PELÁEZ
-
Publication number: 20180002273Abstract: The present invention refers to new amorphous and crystalline solid forms of desvenlafaxine, also known as O-desmethylvenlafaxine or desmethylvenlafaxine, and to its salts, solvates, hydrates and polymorphs thereof, as well as to their use in the manufacture of a pharmaceutical composition useful in the treatment of depression and/or as a selective serotonin and norepinephrine reuptake inhibitor and also in menopause-associated vasomotor disorders.Type: ApplicationFiled: June 29, 2017Publication date: January 4, 2018Inventors: Jorge Guillermo DOMÍNGUEZ CHÁVEZ, Karina MONDRAGÓN VÁSQUEZ, Hugo MORALES ROJAS, Dea HERRERA RUIZ, Herbert HÖPFL, Reyna REYES MARTÍNEZ, Javier HERNÁNDEZ ILLESCAS, Juan Pablo SENOSIAIN PELÁEZ
-
Patent number: 9433602Abstract: The present invention relates to the pharmaceutical field, especially the field of combination and pharmaceutical compositions that comprise a lipase inhibitor and a phytoalexin and pharmaceutically acceptable vehicles or excipients; the present invention also relates to the method for manufacturing compositions containing the combination and the use of said composition in the treatment of conditions of excess weight, obesity and related health problems.Type: GrantFiled: December 16, 2011Date of Patent: September 6, 2016Assignee: LABORATORIOS SENOSIAIN S.A. DE C.V.Inventors: Juan Pablo Senosiain Peláez, Gustavo Barranco Hernandez, Raul Garcia Salgado Lopez
-
Patent number: 9290492Abstract: The invention relates to novel solid forms of fluoroquinolones, in particular to complex co-crystals and to solvates, hydrates and polymorphs thereof. These substances can be used to prepare a pharmaceutical composition containing same as an active ingredient, which can be used as an antibiotic. The compounds have a storage stability that is constant and above that of the salts or hydrates thereof.Type: GrantFiled: April 27, 2012Date of Patent: March 22, 2016Assignee: Laboratorios Senosiain S.A. de C.V.Inventors: Hugo Morales Rojas, Jorge Guillermo Domínguez Chávez, Dea Herrera Ruiz, Herbert Höpfl, Juan Manuel Martínez Alejo, Juan Pablo Senosiain Peláez
-
Patent number: 9278970Abstract: The present invention relates to co-crystals of tadalafil with hydroxyl-substituted benzoic acid coformers having the following structure. Said co-crystals can be used to produce a pharmaceutical composition containing the same as the useful active ingredient. Said co-crystals can exhibit a constant storage stability.Type: GrantFiled: July 6, 2013Date of Patent: March 8, 2016Assignee: Laboratorios Senosiain S.A. de C.V.Inventors: Dea Herrera Ruiz, Karina Mondragón Vásquez, Hugo Morales Rojas, Herbert Höpfl, Juan Pablo Senosiain Peláez
-
Patent number: 9186342Abstract: The invention relates to an oral pharmaceutical composition comprising the combination of an ibuprofen salt or S(+)-ibuprofen with L-arginine and/or the pharmaceutically acceptable salts thereof, and additionally pharmaceutically acceptable vehicles and/or excipients. The invention also relates to the method of producing the composition and to the use of said composition having synergic therapeutic activity, for treating moderate to severe inflammatory pain, fever and inflammation.Type: GrantFiled: April 28, 2011Date of Patent: November 17, 2015Assignee: LABORATORIOS SENOSIAIN S.A. DE C.V.Inventors: Juan Pablo Senosiain Peláez, Angélica Arzola Paniagua, Enrique Raúl García-Salgado López
-
Publication number: 20150152107Abstract: The present invention relates to novel solid forms of phosphodiesterase type 5 (PDE5) inhibitors, especially to complex co-crystals, and to the solvates and/or the polymorphs of same. Said substances can be used to produce a pharmaceutical composition containing same as the useful active ingredient. Said compounds can exhibit a constant storage stability.Type: ApplicationFiled: July 6, 2013Publication date: June 4, 2015Inventors: Dea Herrera Ruiz, Karina Mondragón Vásquez, Hugo Morales Rojas, Herbert Höpf, Juan Pablo Senosiain Peláez
-
Patent number: 8846708Abstract: The present invention relates to a salt of a pyrimidin derivative of the acid (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamide)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic, to a method for preparing same and to the use thereof in formulating pharmaceutical formulations.Type: GrantFiled: October 4, 2011Date of Patent: September 30, 2014Assignee: Laboratorios Senosiain S.A. de C.V.Inventors: Juan Pablo Senosiain Peláez, Héctor Senosiain Arroyo, Manuel Francisco Lara Ochoa
-
Publication number: 20140088116Abstract: The invention relates to novel solid forms of fluoroquinolones, in particular to complex co-crystals and to solvates, hydrates and polymorphs thereof. These substances can be used to prepare a pharmaceutical composition containing same as an active ingredient, which can be used as an antibiotic. The compounds have a storage stability that is constant and above that of the salts or hydrates thereof.Type: ApplicationFiled: April 27, 2012Publication date: March 27, 2014Applicant: LABORATORIOS SENOSIAIN S.A. DE C.V.Inventors: Hugo Morales Rojas, Jorge Guillermo Domínguez Chávez, Dea Herrera Ruiz, Herbert Höpfl, Juan Manuel Martínez Alejo, Juan Pablo Senosiain Peláez
-
Publication number: 20130316005Abstract: The present invention relates to the pharmaceutical field, especially the field of combination and pharmaceutical compositions that comprise a lipase inhibitor and a phytoalexin and pharmaceutically acceptable vehicles or excipients; the present invention also relates to the method for manufacturing compositions containing the combination and the use of said composition in the treatment of conditions of excess weight, obesity and related health problems.Type: ApplicationFiled: December 16, 2011Publication date: November 28, 2013Applicant: LABORATORIOS SENOSIAIN S.A. DE C.V.Inventors: Juan Pablo Senosiain Peláez, Gustavo Barranco Hernandez, Raul Garcia Salgado Lopez
-
Publication number: 20130210848Abstract: The present invention relates to a salt of a pyrimidin derivative of the acid (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamide)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic, to a method for preparing same and to the use thereof in formulating pharmaceutical formulations.Type: ApplicationFiled: October 4, 2011Publication date: August 15, 2013Applicant: LABORATORIOS SENOSIAIN S.A. DE C.V.Inventors: Juan Pablo Senosiain Peláez, Héctor Senosiain Arroyo, Manuel Francisco Lara Ochoa
-
Publication number: 20130109754Abstract: The invention relates to an oral pharmaceutical composition comprising the combination of an ibuprofen salt or S(+)-ibuprofen with L-arginine and/or the pharmaceutically acceptable salts thereof, and additionally pharmaceutically acceptable vehicles and/or excipients. The invention also relates to the method of producing the composition and to the use of said composition having synergic therapeutic activity, for treating moderate to severe inflammatory pain, fever and inflammation.Type: ApplicationFiled: April 28, 2011Publication date: May 2, 2013Applicant: LABORATORIOS SENOSIAIN S.A. DE C.V.Inventors: Juan Pablo Senosiain Peláez, Angélica Arzola Paniagua, Enrique Raúl García-Salgado López
-
Publication number: 20110166087Abstract: The present invention relates to a solid oral pharmaceutical composition comprising fluconazole, tinidazole and clindamycin or a pharmaceutically acceptable salt thereof, wherein the content of pharmaceutically acceptable excipients is significantly lower than the content of the active principles, the use of said composition for oral administration with therapeutic activity for treating sexually transmitted infections.Type: ApplicationFiled: September 4, 2009Publication date: July 7, 2011Inventors: Raúl García Salgado López, Angélica Arzola Paniagua, Juán Pablo Senosiain Peláez, Gustavo Barranco Hernández